nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial
P. A. Philip(The Barbara Ann Karmanos Cancer Institute), Pascal Hammel(Hôpital Paul-Brousse), Roberto Pazo-Cid(Hospital Universitario Miguel Servet), Christophe Borg(Centre Hospitalier Universitaire de Besançon), F. Rivera Herrero(Marqués de Valdecilla University Hospital), Eric Terrebonne(Hôpital Cardiologique du Haut-Lévêque), E.S. Kim(Levine Cancer Institute), Jill Lacy(Smilow Cancer Hospital), Teng Jin Ong, Ahmed Zakari(Florida Hospital Cancer Institute), Alberto F. Sobrero(Ospedale Policlinico San Martino), Scot Dowden, José Luis Manzano Mozo(Sorbonne Université), J. Shiansong Li, F. Portales(Institut de Recherche en Cancérologie de Montpellier), Trevor L. Nydam
Cited by 3
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914